# Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics

Page: https://stenobird.com/podcast/touching-base-6714887/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics
Text version: https://stenobird.com/podcast/touching-base-6714887/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics.md
Podcast: [Touching Base](https://stenobird.com/podcast/touching-base-6714887)
Published: 2026-07-17T01:51:51+00:00
Episode link: https://shows.acast.com/touching-base/episodes/parkinsons-in-the-clinic-insilico-enters-phase-iii-vertex-ac
Audio file: https://sphinx.acast.com/p/open/s/65736d39d32e730012c98919/e/6a598ab67a878a3380370304/media.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics
Duration seconds: 1942

## Resource

Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion.     Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.       Listed below are links to the GEN stories referenced in this episode of Touching Base :     Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice   GEN , July 9, 2026    Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial   GEN , July 9, 2026    Pharma Races to Scale AI as Billions Flow into Drug Discovery   By Fay Lin, PhD, GEN Edge , July 6, 2026    StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III   By Alex Philippidis, GEN Edge , July 12, 2026    Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout   By Alex Philippidis, GEN Edge , July 7, 2026    Top 20 Drugs Heading for the Patent Cliff, 2026-2029   By Alex Philippidis, GEN Magazine , Nov 1, 2025    Touching Base Podcast   Hosted…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/touching-base-6714887/parkinson-s-in-the-clinic-insilico-enters-phase-iii-vertex-acquires-crinetics.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.